Total
0
Shares
DIAGNOS - President, André Larente - The Market Herald Canada
President, André Larente
Source: La Presse
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medical technology company, DIAGNOS (ADK) has revealed a new service agreement with the Colombian Telemedicine Centre (CTMC)
  • The CTMC will use the company’s AI engine CARA to begin screening Colombia’s population for eye-related issues
  • CARA (Computer Assisted Retina Analysis) integrates with existing equipment, and makes standard retinal images sharper, clearer, and easier to read
  • The two parties plan to begin the screening project in two major regions of Colombia in the following weeks
  • Before the market opens, DIAGNOS (ADK) is trading at C$0.17 per share 

Medical technology company, DIAGNOS (ADK) has revealed a new service agreement with the Colombian Telemedicine Centre (CTMC).

The CTMC has chosen DIAGNOS and its artificial intelligence engine, CARA, for a screening project. In alliance with the country's largest specialist centre, the CTMC will use CARA to screen Colombia’s population for eye-related issues.

The CTMC’s founder, Dr Jorge Alberto Velez B, said this will unburden the heavy costs of blindness caused by diabetes.

CARA (Computer Assisted Retina Analysis) is a tele-ophthalmology platform that integrates with pre-existing hardware or software. The tool’s image enhancement algorithms make standard images of a person’s retina sharper, clearer, and easier to read. 

CARA can process results at the point of care, which will empower local technicians. However, specialists will validate the automated results before scheduling follow-ups with patients requiring further treatment.  

The CTMC and DIAGNOS plan to start the screening project in two major regions of Colombia, in the coming weeks.

DIAGNOS’ President, André Larente, commented on the service agreement with Colombia’s Telemedicine Centre. 

“We would like to thank the CTMC for choosing our CARA platform. We believe that CARA is a perfect fit as the main engine of the telemedicine solution.

“After a successful eye screening program with Bayer in 2015, we return to Colombia to engage our AI service into a practical solution for the local community. Along with CTMC, we can add value by making our unique service accessible,” he said. 

Before the market opens, DIAGNOS (ADK) is trading at C$0.17 per share.

More From The Market Herald
Intema Solutions shares jump 50pc on $1.5M deal with Vida Life AI

" VitalHub (TSXV:VHI) to purchase on-site hospital queue management system from Jayex for £1.3 million

VitalHub has announced that it has signed an agreement with Jayex Healthcare to purchase the assets of Jayex’s on-premise hospital queue management system.
Cardiol (TSX:CRDL) announces topline results from Phase I trial for CardiolRx

" Cardiol (TSX:CRDL) announces topline results from Phase I trial for CardiolRx

Cardiol Therapeutics (CRDL) has shared topline results from its Phase I single and multiple ascending dose clinical trial for CardiolRx.
Resverlogix - President and CEO, Donald McCaffrey - The Market Herald Canada

" Health Canada authorizes Resverlogix (TSX:RVX) to begin clinical studies of Apabetalone for COVID-19

Resverlogix Corp. (RVX) is pleased to announce that Health Canada has approved the COVID-19 Clinical Trial Application for apabetalone.
Noranda Income Fund (TSX:NIF.UN) supports mass vaccination efforts in Salaberry-de-Valleyfield region

" Noranda Income Fund (TSX:NIF.UN) supports mass vaccination efforts in Salaberry-de-Valleyfield region

Noranda Income Fund has entered into a partnership to finance a mobile vaccination clinic.